From 1 September 2026, specialised accreditation is no longer
required for medical practitioners and authorised nurse practitioners to prescribe
hepatitis B and hepatitis C medicines accessed through the Pharmaceutical
Benefits Scheme (PBS) Section 100 (s100) Highly Specialised Drugs Program.1
Education
and training programs for prescribing
these medicines will still be available but are no longer mandated.2,3
This change comes after extensive advocacy and consultation and
aims to increase timely access to treatment, particularly in regional, rural
and remote areas where access to accredited prescribers has been most limited.4
Medical and authorised nurse practitioner prescribers are still
required to make sure patient eligibility criteria are met, as per the General Statement for Drugs for the Treatment of Hepatitis C and Treatment
of chronic hepatitis B virus infection, and to prescribe within
jurisdictional regulations and their scope of practice.2
The World Health Organization has an ongoing commitment to
elimination of viral hepatitis as a public health threat5
that is supported by the Australian Government and reflected in the Fourth National
Hepatitis B Strategy 2025–2030 and the Sixth National
Hepatitis C Strategy 2025–2030. Increasing access to treatment
is a key focus of both strategies.
Australian Prescriber welcomes Feedback.